Scroll To Top
Health

FDA approves new
formulation of Kaletra

FDA approves new
formulation of Kaletra

The Food and Drug Administration on Friday approved a tablet form of Abbott Laboratories' protease inhibitor Kaletra. The new tablet formulation does not require refrigeration, as the previous formulation of Kaletra did, and reduces a patient's pill burden from six capsules per day to four tablets. The new Kaletra tablet also can be taken with or without food. Kaletra, which includes a small booster dose of Norvir within the same pill as the drug's other active ingredient, lopinavir, is the world's most commonly prescribed protease inhibitor, according to Abbott officials. (Advocate.com)

Advocate Magazine - KehlaniAdvocate Magazine - Gus Kenworthy

From our Sponsors

Most Popular

Latest Stories